Associations - Peripheral T-cell Lymphoma

TNFRSF8 expression TNFRSF8 expression	Peripheral T-cell Lymphoma Peripheral T-cell Lymphoma	brentuximab vedotin Sensitive: A1 - Approval
No biomarker No biomarker	Peripheral T-cell Lymphoma Peripheral T-cell Lymphoma	belinostat Sensitive: A1 - Approval
No biomarker No biomarker	Peripheral T-cell Lymphoma Peripheral T-cell Lymphoma	pralatrexate Sensitive: A1 - Approval
No biomarker No biomarker	Peripheral T-cell Lymphoma Peripheral T-cell Lymphoma	brentuximab vedotin Sensitive: A1 - Approval
No biomarker No biomarker	Peripheral T-cell Lymphoma Peripheral T-cell Lymphoma	denileukin diftitox Sensitive: A1 - Approval
ALK positive ALK positive	Peripheral T-cell Lymphoma Peripheral T-cell Lymphoma	crizotinib Sensitive: A2 - Guideline
No biomarker No biomarker	Peripheral T-cell Lymphoma Peripheral T-cell Lymphoma	etoposide IV Sensitive: A2 - Guideline
No biomarker No biomarker	Peripheral T-cell Lymphoma Peripheral T-cell Lymphoma	cyclophosphamide oral Sensitive: A2 - Guideline
No biomarker No biomarker	Peripheral T-cell Lymphoma Peripheral T-cell Lymphoma	cyclophosphamide oral + etoposide IV Sensitive: A2 - Guideline
No biomarker No biomarker	Peripheral T-cell Lymphoma Peripheral T-cell Lymphoma	bortezomib Sensitive: A2 - Guideline
No biomarker No biomarker	Peripheral T-cell Lymphoma Peripheral T-cell Lymphoma	bendamustine Sensitive: A2 - Guideline
No biomarker No biomarker	Peripheral T-cell Lymphoma Peripheral T-cell Lymphoma	alemtuzumab Sensitive: A2 - Guideline
No biomarker No biomarker	Peripheral T-cell Lymphoma Peripheral T-cell Lymphoma	lenalidomide Sensitive: A2 - Guideline
No biomarker No biomarker	Peripheral T-cell Lymphoma Peripheral T-cell Lymphoma	gemcitabine Sensitive: A2 - Guideline
No biomarker No biomarker	Peripheral T-cell Lymphoma Peripheral T-cell Lymphoma	RP6530 Sensitive: B - Late Trials
IL2RA expression IL2RA expression	Peripheral T-cell Lymphoma Peripheral T-cell Lymphoma	denileukin diftitox Sensitive: C1 - Off-label
PD-L1 overexpression PD-L1 overexpression	Peripheral T-cell Lymphoma Peripheral T-cell Lymphoma	GB226 Sensitive: C3 – Early Trials
PD-1 overexpression PD-1 overexpression	Peripheral T-cell Lymphoma Peripheral T-cell Lymphoma	nivolumab Sensitive: C3 – Early Trials
RHOA mutation RHOA mutation	Peripheral T-cell Lymphoma Peripheral T-cell Lymphoma	copanlisib Sensitive: C3 – Early Trials
IDH2 mutation IDH2 mutation	Peripheral T-cell Lymphoma Peripheral T-cell Lymphoma	copanlisib Sensitive: C3 – Early Trials
TSC2 mutation TSC2 mutation	Peripheral T-cell Lymphoma Peripheral T-cell Lymphoma	copanlisib Sensitive: C3 – Early Trials
TNFRSF8 positive TNFRSF8 positive	Peripheral T-cell Lymphoma Peripheral T-cell Lymphoma	BV-ICE Sensitive: C3 – Early Trials
IL10-H IL10-H	Peripheral T-cell Lymphoma Peripheral T-cell Lymphoma	CHOP Resistant: C3 – Early Trials
RPS6 underexpression RPS6 underexpression	Peripheral T-cell Lymphoma Peripheral T-cell Lymphoma	ruxolitinib Sensitive: C3 – Early Trials
TNFRSF8 negative TNFRSF8 negative	Peripheral T-cell Lymphoma Peripheral T-cell Lymphoma	chidamide Sensitive: C3 – Early Trials
TNFRSF8 negative TNFRSF8 negative	Peripheral T-cell Lymphoma Peripheral T-cell Lymphoma	rituximab + lenalidomide + brentuximab vedotin Sensitive: C4 – Case Studies
CD20 overexpression CD20 overexpression	Peripheral T-cell Lymphoma Peripheral T-cell Lymphoma	CVAD Resistant: C4 – Case Studies
CD20 overexpression CD20 overexpression	Peripheral T-cell Lymphoma Peripheral T-cell Lymphoma	rituximab Sensitive: C4 – Case Studies
CD20 overexpression CD20 overexpression	Peripheral T-cell Lymphoma Peripheral T-cell Lymphoma	CEOP-E Resistant: C4 – Case Studies
CD20 overexpression CD20 overexpression	Peripheral T-cell Lymphoma Peripheral T-cell Lymphoma	DICE Resistant: C4 – Case Studies

Peripheral T-cell Lymphoma

Associations(30)

Associations
(30)